With 0.52 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.24 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.1707 whereas the lowest price it dropped to was $3.04. The 52-week range on AVIR shows that it touched its highest point at $4.60 and its lowest point at $2.75 during that stretch. It currently has a 1-year price target of $6.20. Beta for the stock currently stands at 0.20.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AVIR was up-trending over the past week, with a rise of 7.48%, but this was down by -1.86% over a month. Three-month performance dropped to -20.80% while six-month performance fell -9.46%. The stock gained 7.12% in the past year, while it has gained 3.61% so far this year. A look at the trailing 12-month EPS for AVIR yields -2.07 with Next year EPS estimates of -1.58. For the next quarter, that number is -0.29. This implies an EPS growth rate of -10.74% for this year and 12.41% for next year.
Float and Shares Shorts:
At present, 84.46 million AVIR shares are outstanding with a float of 74.42 million shares on hand for trading. On 2024-11-29, short shares totaled 2.61 million, which was 309.0 higher than short shares on 1730332800. In addition to Dr. Jean-Pierre Sommadossi Ph.D. as the firm’s Founder, Chairman, CEO & President, Ms. Andrea J. Corcoran J.D. serves as its CFO, Executive VP of Legal & Secretary.
Institutional Ownership:
Through their ownership of 0.70957 of AVIR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, AVIR reported revenue of $0.0 and operating income of -$37202000.0. The EBITDA in the recently reported quarter was -$37098000.0 and diluted EPS was -$0.37.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With AVIR analysts setting a high price target of 8.0 and a low target of 6.2, the average target price over the next 12 months is 7.4. Based on these targets, AVIR could surge 153.16% to reach the target high and rise by 96.2% to reach the target low. Reaching the average price target will result in a growth of 134.18% from current levels.
Analysts have provided yearly estimates in a range of -$1.74222 being high and -$1.89488 being low. For AVIR, this leads to a yearly average estimate of -$1.80508.
